Examining access to care in clinical genomic research and medicine: Experiences from the CSER Consortium.

TitleExamining access to care in clinical genomic research and medicine: Experiences from the CSER Consortium.
Publication TypeJournal Article
Year of Publication2021
AuthorsGutierrez, AM, Robinson, JO, Outram, SM, Smith, HS, Kraft, SA, Donohue, KE, Biesecker, BB, Brothers, KB, Chen, F, Hailu, B, Hindorff, LA, Hoban, H, Hsu, RL, Knight, SJ, Koenig, BA, Lewis, KL, Lich, KHassmiller, O'Daniel, JM, Okuyama, S, Tomlinson, GE, Waltz, M, Wilfond, BS, Ackerman, SL, Majumder, MA
JournalJ Clin Transl Sci
Volume5
Issue1
Paginatione193
Date Published2021
ISSN2059-8661
Abstract

INTRODUCTION: Ensuring equitable access to health care is a widely agreed-upon goal in medicine, yet access to care is a multidimensional concept that is difficult to measure. Although frameworks exist to evaluate access to care generally, the concept of "access to genomic medicine" is largely unexplored and a clear framework for studying and addressing major dimensions is lacking.

METHODS: Comprised of seven clinical genomic research projects, the Clinical Sequencing Evidence-Generating Research consortium (CSER) presented opportunities to examine access to genomic medicine across diverse contexts. CSER emphasized engaging historically underrepresented and/or underserved populations. We used descriptive analysis of CSER participant survey data and qualitative case studies to explore anticipated and encountered access barriers and interventions to address them.

RESULTS: CSER's enrolled population was largely lower income and racially and ethnically diverse, with many Spanish-preferring individuals. In surveys, less than a fifth (18.7%) of participants reported experiencing barriers to care. However, CSER project case studies revealed a more nuanced picture that highlighted the blurred boundary between access to genomic research and clinical care. Drawing on insights from CSER, we build on an existing framework to characterize the concept and dimensions of access to genomic medicine along with associated measures and improvement strategies.

CONCLUSIONS: Our findings support adopting a broad conceptualization of access to care encompassing multiple dimensions, using mixed methods to study access issues, and investing in innovative improvement strategies. This conceptualization may inform clinical translation of other cutting-edge technologies and contribute to the promotion of equitable, effective, and efficient access to genomic medicine.

DOI10.1017/cts.2021.855
Alternate JournalJ Clin Transl Sci
PubMed ID34888063
PubMed Central IDPMC8634302
Grant ListU01 HG009599 / HG / NHGRI NIH HHS / United States
U01 HG007292 / HG / NHGRI NIH HHS / United States
U01 HG006485 / HG / NHGRI NIH HHS / United States
U24 HG007307 / HG / NHGRI NIH HHS / United States
U01 HG006487 / HG / NHGRI NIH HHS / United States
U01 HG007301 / HG / NHGRI NIH HHS / United States
U01 HG009610 / HG / NHGRI NIH HHS / United States